We are live on ! Find out more
SURF

Surface Oncology, Inc. Common Stock

Delisted

SURF was delisted on the 7th of September, 2023.

47 hedge funds and large institutions have $44.4M invested in Surface Oncology, Inc. Common Stock in 2019 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 12 increasing their positions, 20 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

13% less funds holding

Funds holding: 5447 (-7)

40% less repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 20

43% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 14

43% less capital invested

Capital invested by funds: $78.4M → $44.4M (-$34M)

Holders
47
Holders Change
-7
Holders Change %
-12.96%
% of All Funds
1.02%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
8
Increased
12
Reduced
20
Closed
14
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
AVAI
1
Atlas Venture Associates IX
Massachusetts
$13.1M
NMC
2
NEA Management Company
Maryland
$9.35M
EC
3
EcoR1 Capital
California
$6.52M +$196K +49,200 +2%
BI
4
BVF Inc
California
$2.88M +$2.27M +569,384 +126%
Fidelity International
5
Fidelity International
Bermuda
$1.82M +$24.3K +6,104 +1%
Vanguard Group
6
Vanguard Group
Pennsylvania
$1.66M -$126K -31,573 -5%
BlackRock
7
BlackRock
New York
$1.62M -$1.96M -493,312 -46%
Millennium Management
8
Millennium Management
New York
$1.54M +$839K +210,655 +63%
Victory Capital Management
9
Victory Capital Management
Texas
$1.38M -$134K -33,550 -6%
Fidelity Investments
10
Fidelity Investments
Massachusetts
$895K -$1.08M -272,232 -46%
Citadel Advisors
11
Citadel Advisors
Florida
$838K -$604K -151,712 -34%
Northern Trust
12
Northern Trust
Illinois
$311K -$29.4K -7,398 -6%
Acadian Asset Management
13
Acadian Asset Management
Massachusetts
$283K +$30.4K +7,640 +8%
Bank of America
14
Bank of America
North Carolina
$273K +$19.9K +5,008 +5%
Jacobs Levy Equity Management
15
Jacobs Levy Equity Management
New Jersey
$265K +$9.95K +2,500 +3%
Geode Capital Management
16
Geode Capital Management
Massachusetts
$221K -$178K -44,596 -36%
SB
17
Samsara BioCapital
California
$221K
Goldman Sachs
18
Goldman Sachs
New York
$137K -$66K -16,586 -25%
PP
19
Paloma Partners
Connecticut
$119K +$169K +42,374 New
Bank of New York Mellon
20
Bank of New York Mellon
New York
$108K -$85.3K -21,437 -36%
SIM
21
Spark Investment Management
New York
$107K -$4.06K -1,021 -3%
Jane Street
22
Jane Street
New York
$82K +$116K +29,111 New
OAM
23
Oxford Asset Management
United Kingdom
$75K +$16.8K +4,219 +19%
Barclays
24
Barclays
United Kingdom
$71K +$87.4K +21,960 +628%
Renaissance Technologies
25
Renaissance Technologies
New York
$65K +$92.3K +23,200 New

SURF Hedge Fund Activity: Q2 2019 in Review

47 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Surface Oncology, Inc. Common Stock (SURF) for Q2 2019, worth a combined $44.4M — down 43% from $78.4M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of SURF and 8 opened new positions — a net loss of 6 holders — while 20 trimmed existing stakes and 12 added.

The largest buyer was BVF Inc, adding an estimated $2.27M. The largest seller was BlackRock, cutting an estimated $1.96M.

  • 47 institutional investors held Surface Oncology, Inc. Common Stock (SURF) as of Q2 2019, down from 54 in Q1 2019.
  • Funds reported $44.4M of Surface Oncology, Inc. Common Stock stock for Q2 2019, down 43% quarter-over-quarter.
  • 8 funds opened new Surface Oncology, Inc. Common Stock positions in Q2 2019 and 14 closed out, a net change of -6 holders.
  • The largest Surface Oncology, Inc. Common Stock buyer in Q2 2019 was BVF Inc, an estimated $2.27M added.
  • The largest Surface Oncology, Inc. Common Stock seller in Q2 2019 was BlackRock, an estimated $1.96M sold.

Based on aggregated 13F filings for Q2 2019.